Business
Futura Medical plc Total Voting Rights
Futura Medical plc Total Voting Rights.
About this update from Futura Medical Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 9324T\n Futura Medical PLC\n 30 November 2021\n \n \n \n 30 November 2021\n \n \n \n \n \n Futura Medical plc\n \n \n \n (\"Futura\" or the \"Company\")\n \n Total Voting Rights\n Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products for sexual health and pain relief, for the purposes of the FCA's Disclosure and Transparency Rules, the Company's total issued share capital at the date of this announcement is 287,150,971 Ordinary Shares.\n \n Since the Company currently holds no shares in treasury, the total number of voting rights in the Company is 287,150,971 and this figure may therefore be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.\n \n \n \n ENDS\n \n For further information please contact:\n \n Futura Medical plc \nJames Barder, Chief Executive\nAngela Hildreth, Finance Director and COO\n Email: [email protected]\nTel: +44 (0) 1483 685 670\n \n Nominated Adviser and Sole Broker:\n \n Liberum\n \nRichard Lindley/ Kane Collings\nTel: +44 (0) 20 3100 2000\n \n For media enquiries please contact:\n Optimum Strategic Communications\n Mary Clark/ Eva Haas/ Hollie Vile\n Email: [email protected]\n Tel: +44 (0) 20 3922 0891\n \n Notes to editors:\n \n About Futura Medical plc\n \n Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® technology. Each DermaSys® formulation is separately patented and specifically tailored for the selected indication and application, as well as being optimised for clinical efficacy, safety, administration and patient convenience. The products are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.\n \n \n \n \n \n MED3000 is Futura's topical gel formulation that is a bre...